Key appointment as company seeks to continue global expansion of microphysiological systems and contract research service offerings CN Bio, a leading Organ-on-a-chip (OOC) company that designs and
CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
The next-generation platform combines CN Bio’s in vitro 3D liver model, whose phenotype and functions mimic that in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a key milestone in the Company’s mission to develop the most complete human ‘body-on-a-chip’ in the laboratory, the PhysioMimix OOC Multi-Organ MPS will provide advanced insights into the potential effects of novel therapeutics that were previously only achievable using animal models.
CN Bio introduces the PhysioMimix OOC Multi-Organ Microphysiological System
Expands portfolio of easy-to-use, robust and reliable human-relevant in vitro models, for fast-tracked drug discovery and development
System to be launched at Society of Toxicology s 2021 Virtual Annual Meeting, 12
th 26
th March 2021
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix OOC Multi-Organ MPS. The next-generation platform combines CN Bio s
in vitro 3D liver model, whose phenotype and functions mimic that
in vivo, with a range of other organs to more accurately recapitulate the multi-organ and systemic effects observed in humans. Demonstrating a key milestone in the Company s mission to develop the most complete human body-on-a-chip in the laboratory, the PhysioMimix OOC Multi-Organ MPS will provide advanced insights into the potential effects of nov